Sign in
CompletedNo phase

Parent Artery Reconstruction for Cerebral Aneurysms Using a Novel Flow Diverter With Surface Modification

Key facts

Who runs it
Sinomed Neurovita Technology Inc.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
143 people enrolled
Started
27 Mar 2023
Ended
30 Aug 2024
Type of study
Interventional
Treatments tested
  • Cerebral flow diverter
Record updated
13 July 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 18 years to 75 years, male or non-pregnant female
  • Unruptured wide-necked cerebral aneurysms confirmed by preoperative imaging (Wide-necked is defined as width ≥ 4 mm or a dome-to-neck ratio < 2)
  • Parent vessel with a diameter range of 1.75-6.0 mm
  • Those who voluntarily participate in the study and sign informed consent form

Who cannot take part

  • Subject with target aneurysms are blood blister-like aneurysms, pseudoaneurysms, arteriovenous malformation, moyamoya disease-related aneurysm, or multiple aneurysms that cannot be treated with a single stent
  • Subject with target aneurysm previously treated with craniotomy or other endovascular interventional therapy
  • Known sensitivity to antiplatelet medications, anticoagulant medications, radiographic contrast agents, anesthetic, nickel, platinum-tungsten alloy, platinum-iridium alloy, and poly-N-[Tris(hydroxymethyl)methyl] acrylamide (poly-NTMA)
  • Hospitalized surgical treatment within the previous 30 days or planned within the next 180 days after operation
  • All subjects who are participating in other drug/medical device clinical trials and have not completed the programme requirements
  • Severe respiratory system, liver and kidney diseases (such as creatinine ≥ 3.0 mg/dL (except dialysis)) or blood coagulation disorders before operation
  • Platelet count is less than 100×109/L, international normalized ratio (INR) is more than 1.5
  • Severe arteriosclerosis or tortuosity of intracranial artery, and the device is difficult to reach the target vessel
  • Severe neurological deficit that renders the patient incapable of living independently (modified Rankin score ≥3)
  • The survival expectation is less than 1 year
  • Inapplicable for this study at the investigators' viewpoints

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this trial is to evaluate the safety and efficacy of the cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms

The group in the trial

  • Cerebral flow diverterTreatment being tested

    The cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multi-center, Single Arm Clinical Study to Evaluate the Safety and Effectiveness of the Flow Diverter Stent System in the Treatment of Cerebral Aneurysms
Record updated
13 July 2026